Armata Pharmaceuticals (ARMP) Cash & Equivalents (2013 - 2026)

Armata Pharmaceuticals (ARMP) has 14 years of Cash & Equivalents data on file, last reported at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 58.93% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (down 58.93% YoY), and the FY2025 full-year result was $8.7 million, down 6.49% from the prior year.
• Cash & Equivalents declined to $4.8 million in Q1 2026, from $8.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $46.4 million in Q1 2022 to a low of $4.3 million in Q2 2025.
• A 5-year average of $19.6 million and a median of $14.9 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 111.99% in 2024 and tumbled 83.61% in 2025, its largest moves.
• Tracing ARMP's Cash & Equivalents over 5 years: stood at $14.9 million in 2022, then retreated by 8.95% to $13.5 million in 2023, then sank by 31.29% to $9.3 million in 2024, then declined by 6.49% to $8.7 million in 2025, then tumbled by 44.75% to $4.8 million in 2026.
• Business Quant data shows ARMP's Cash & Equivalents at $4.8 million in Q1 2026, $8.7 million in Q4 2025, and $14.8 million in Q3 2025.